A61K 31/708(20130101), A61K 38/22(20130101), C07K 14/58(20130101), Y10S 930/05(20130101)
A method of treating cancer through use of guanosine 3′,5′-cyclic monophosphate (cyclic GMP). Cyclic GMP decreases the number of human breast cancer and prostate adenocarcinoma as well as small-cell and squamous lung cells in culture by 30% (1 μM), 84% (1 mM), 31% (1 μM), and 30% (1 μM), respectively. Cyclic GMP decreases DNA synthesis in human pancreatic, breast, and prostate adenocarcinomas as well as small-cell and squamous cell carcinomas of the lung at its 1 μM concentration by 51%, 54%, 56%, 50% and 52%, respectively. Cyclic GMP when infused for one week decreases the tumor volume of human pancreatic adenocarcinomas in athymic mice 95% compared to untreated animals with human pancreatic adenocarcinomas.
Vesely, David L., "Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)" (2014). USF Patents. 131.
University of South Florida